Dual GIP/GLP-1 Agonists for Hepatic Steatosis and Fibrosis in Type 2 Diabetes with NAFLD

Authors

  • Abid Ali, Habiba Sajjad, Arooj Fatimah, Usman Aslam, Jazib Andleeb, Muhammad Usman

Keywords:

tirzepatide, GIP/GLP-1 dual agonist, NAFLD, MRI-PDFF, fibrosis

Abstract

Nonalcoholic fatty liver disease (NAFLD) is highly prevalent among persons with type 2 diabetesmellitus (T2DM) and ranges from simple steatosis to metabolic dysfunction–associatedsteatohepatitis (MASH) with progressive fibrosis. Dual agonists of glucose-dependent
insulinotropic peptide (GIP) and glucagon-like peptide

References

Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic DysfunctionAssociated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299–310. DOI: 10.1056/NEJMoa2401943. (PubMed)

Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy. Lancet Diabetes Endocrinol. 2022;10(6):393–406. DOI: 10.1016/S2213-8587(22)00070-5. (PubMed)

Downloads

Published

2025-09-22

How to Cite

Abid Ali, Habiba Sajjad, Arooj Fatimah, Usman Aslam, Jazib Andleeb, Muhammad Usman. (2025). Dual GIP/GLP-1 Agonists for Hepatic Steatosis and Fibrosis in Type 2 Diabetes with NAFLD . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 2085–2093. Retrieved from https://ijprt.org/index.php/pub/article/view/1014

Issue

Vol. 15 No. 2 (2025)

Section

Research Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.